The Biden administration announced the first 10 prescription drugs that will be subject to price negotiations between manufacturers and Medicare as part of the Inflation Reduction Act. The drugs subject to the initial talks this year are Eliquis, made by Bristol-Myers Squibb (BMY), Jardiance, made by Eli Lilly (LLY), Xarelto, made by Johnson & Johnson (JNJ), Januvia, made by Merck (MRK), Farxiga, made by AstraZeneca (AZN), Entresto, made by Novartis (NVS), Enbrel, made by Amgen (AMGN), Imbruvica, made by AbbVie (ABBV), Stelara, made by Johnson & Johnson, and Fiasp and NovoLog insulins made by Novo Nordisk (NVO).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Drug Companies Mixed as Medicare Plans to Negotiate
- Bristol Myers announces FDA approval for Reblozyl
- Bristol Myers announces long-term follow-up data from Phase 3 studies of CAMZYOS
- Bristol Myers has joined Cellares’ TAP program
- Bristol Myers Squibb-Pfizer Alliance presents ATHENS results at ESC Congress
